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Abstract  
Background:  
Hepatocyte  aberrations,  accumulation  of  chromosomal  damage  and  possibly  initiation  of 
hepatic  carcinogenesis  is  thought  to  be  caused  by  the  continued  viral  replication  and  the 
persistent  attempt  by  a  less  than  optimal  immune  response  to  eliminate  hepatitis  C  virus 
(HCV) infected cells. The identification of the “death factors" including  Fas and its Ligand 
(Fas-L) as a major regulator of both apoptosis and immune function has provided insight into 
an attractive mechanism of tumor escape from immune clearance.  
Aim: To assess the hepatic expression of Fas/Fas-L, the Fas receptor (Fas-R) expression on 
lymphocyte,  and  serum  soluble  Fas  (sFas)  in  an  attempt  to  analyze  the  role  of  Fas 
receptor/ligand system in the multistep process of fibrosis/carcinogenesis and the possible use 
of the serum marker as possible candidate biomarkers for an early detection of hepatocellular 
carcinoma (HCC). 
 
Material and Method: 
 The current study included 100 samples from cases at Theodor Bilharz Research Institute and 
Kasr Al Aini Hospital in Egypt. There were 90 cases of chronic hepatitis C (CHC) infection 
(and  negative  hepatitis  B  virus  infection).  There  were  30  cases  without  liver  cirrhosis,  30 
cases with liver cirrhosis and 30 cases with HCC. 10 liver biopsies were taken from healthy 
livers as normal controls. Histopathologic study and immunohistochemistry for detection of 
hepatic Fas and Fas-L expression were determined for all cases. Electron microscopy (EM) 
and  immunoelectron  microscopy  (IEM)  examination  for  detection  of  Fas-R  expression  on 
lymphocytes were also done. sFas, liver function tests, serologic markers for viral hepatitis, 
and serum alpha-fetoprotein level (alpha-FP) were done. 
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Results: 
 The sFas in both HCC and CHC with cirrhosis patients were significantly higher than those 
of  normal  controls  and  CHC  without  cirrhosis  (P<0.01),  but  there  was  no  significant 
difference between the cirrhosis and HCC patients. Positive hepatic expression of  both Fas 
and  Fas-L  were  significantly  increased  in  the  diseased  groups  (p<0.  01)  compared  to  the 
control specimens. A progressive Fas and FasL increase from CHC without cirrhosis to CHC 
with cirrhosis followed by a decline from the latter to HCC. Apoptotic Fas and Fas-L proteins 
expression  was  significantly  increased  with  the  necroinflammatory  activity  and  the 
advancement of fibrosis. There was a non-significant negative correlation between sFas and 
hepatic Fas. In addition a significant over expression of Fas-R on separated lymphocytes was 
associated with a higher frequency of apoptotic cell death as detected by EM examination.  
Conclusion: 
 The Fas receptor/ligand system was significantly  involved in the process of liver  cirrhosis 
converting into HCC. Down-regulation of Fas expression, up-regulation of Fas-L expression 
in  hepatocytes  and  elevation  of  serum  sFas  level  were  important  in  tumor  evasion  from 
immune surveillance and in hepatic carcinogenesis. 
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Introduction 
  Hepatitis C Virus (HCV) is recognized as 
a major threat to global public health. An 
estimated  170  million  people  worldwide 
are infected, most of them are chronically 
infected and at risk for liver cirrhosis and 
hepatocellular  carcinoma  (HCC)  (Coulon 
et  al.,  2010).  Immunophenotyping  of 
intrahepatic infiltrating inflammatory cells 
in  chronic  hepatitis  C  (CHC)  patients 
showed a predominance of T-lymphocytes 
cells, with a significant proportion  
of CD4+ and CD8+ cells, suggesting that 
the  host  immune  system  is  involved  in 
liver  disease  pathogenesis  (Onji  et  al., 
1992). The continued viral replication and 
persistent  attempt  by  a  less  than  optimal 
immune  response  to  eliminate  HCV-
infected cells are implicated in hepatocyte 
aberrations, accumulation of chromosomal 
damage and possibly initiation of hepatic 
carcinogenesis  (Ahn  et  al.,  2004).Olfat Hammam et Al  
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            Our immune system, charged with 
the  function  of  cancer  surveillance,  has 
complex  and  efficient  capability  to  clear 
genetically  altered  cells  that  have 
undergone  malignant  transformation. 
Tumor  cells  must  develop  strategies  to 
avoid clearance by the immune system to 
survive,  expand  their  populations  and 
metastasize  (Patel,  1999).  The 
identification  of  the  “death  factors" 
including Fas and its Ligand (Fas-L) as a 
major  regulator  of  both  apoptosis  and 
immune function has provided insight into 
an attractive  mechanism  of tumor  escape 
from immune clearance (Nagata, 1997). 
        Fas  and  Fas-L  are  transmembrane 
proteins  of  the  tumor  necrosis  factor 
family  of  receptors  and  ligands. 
Engagement  of  Fas  by  Fas-L  triggers  a 
cascade of well-characterized intracellular 
signaling  events  that  culminate  in  cell 
death  by  apoptosis  (Nagata  and 
Goldstein, 1995). Fas receptors are widely 
expressed in normal and diseased tissues. 
It  has  been  implicated  in  tumor 
progression  of  several  cancers  (Viard-
Leveugle  et  al.,  2003;Bebenek  et  al., 
2008). 
Fas-L  is  expressed  mainly  in 
cytotoxic  T-lymphocyte  (Suda  et  al., 
1993),  immune  privileged  sites  (Griffith 
et al., 1995) and in various tumors where 
specific  cytotoxic  T-cell  clones  are 
produced  (Lee  et  al.,  1998).  Fas-L  over 
expression  was  found  to  be  related  to 
advanced  stage  in  many  tumors  (Viard-
Leveugle  et  al.,  2003;Pryczynicz  et  al., 
2010). 
 Apoptosis  is  tightly  regulated 
throughout a  variety  of  mechanisms, one 
of which is postulated to be the production 
of  sFas  which  is  an  antagonistic  decay 
protein similar to Fas, except that it lacks 
the  transmembrane  domain.  It  normally 
binds to FasL, thus blocking the signaling 
of  the  membrane-bound  form  of  Fas. 
Elaboration  of  sFas  by  tumor  cells,  by 
alternative  mRNA  splicing,  may 
contribute  to  resistance  to  Fas-mediated 
apoptosis (Nagao et al., 1999). 
  Therefore,  due  to  the  importance 
of the Fas system members (Fas, FasL and 
sFas),  this  study  was  designed  to  assess 
the hepatic tissue expression of Fas/FasL , 
Fas  receptor  (FasR)    expression  on  T-
lymphocytes  using    electron  microscope 
(EM)  and  immunoelectron  microscope 
(IEM)  examination  and  the  circulating 
serum level of sFas in chronic hepatitis C 
liver disease, to analyze the role of these 
factors  in  the  multistep  process  of 
fibrosis/carcinogenesis  and  the  possible 
use  of  the  serum  marker  as  possible 
candidate  biomarkers  for  an  early 
detection of HCC. 
Patients and Methods 
 
This  study  enrolled  90  chronic 
HCV patients (54 males and 36 females), 
age  range  between  24-66  years  with  a Early Detection of Hepatocellular Carcinoma on top of Liver Cirrhosis….  
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mean  of  48.32±7.65  admitted  to  the 
Hepatology  and  Gastroenterology 
Department  at  Theodor  Bilharz  Research 
Institute  (TBRI)  and  Kasr  Al  Aini 
Hospital. Liver and tumor specimens were 
taken  by  surgery  and  endoscopy  from 
hepatectomies. They included  30 cases  of 
chronic hepatitis C virus infection without 
hepatic  cirrhosis,  30  cases  with  hepatic 
cirrhosis and 30 cases with HCC. Patients 
with  liver  disease  of  other  etiology  were 
excluded.  The  diagnosis  of  cirrhotic 
patients was made on the basis of clinical 
history,  clinical  examinations,  laboratory 
findings, gastroscopy and ultrasonography. 
In addition, ten control liver biopsies were 
taken  from  age-  and  sex-matched 
individuals  undergoing  laparoscopic 
cholecystectomy  (7  males  and  3  females, 
age  range  between  31-45  years  with  a 
mean  of  42.21±4.54).  Written  informed 
consent was obtained from all participants 
and  the  TBRI  local  ethical  committee 
approved the study.  
 Sampling 
         Blood  samples  of  8  ml  were 
collected  into  sterile  endotoxin-free 
vacuum  blood  collection  tubes  on 
potassium  EDTA.  The  peripheral  blood 
mononuclear  cell  (PBMNC)  layer  was 
separated  using  Ficoll  Hypaque  (Seromid 
Biochrom,  Berlin,  Germany)  density 
gradient centrifugation and washed 3 times 
with Hank's balanced salt solution (HBSS) 
without  Ca2+  and  Mg2+  ions  (Helmy  et 
al,  2007).  These  cells  were  prepared  for 
EM examination  using  agarose  cell  block 
technique  in  addition  to  the  IEM 
examination. Another 2 ml of blood were 
withdrawn into plain tube and centrifuged 
shortly  after  clot  formation.  All  samples 
were stored at −70°C in aliquots and used 
for analysis of sFas. 
         Formalin-fixed  and  paraffin 
embedded  tissues  from  tumor  samples 
were  used  for  immunohistochemical 
analysis  of  Fas  and  FasL.  Liver  biopsies 
are  analyzed  according  to  a  histological 
METAVIR (Bedossa and Poynard, 1996) 
scoring system. Using two separate scores, 
one  for  necroinflammatory  grade  (A  for 
activity)  A1:  minimal  activity,  A2: 
moderate activity, A3: severe activity and 
another for the stage of fibrosis (F) which 
scores fibrosis from F0-F4, Starting with a 
score  of  F1  with  minimal  fibrosis  and 
increasing  till  F4  signifies  advanced 
fibrosis. 
Routine laboratory investigations:   
       Complete  haemogram  using 
automated  haemogram  (ACT  Differential, 
Beckman,  France).  Liver  function  tests 
were  carried  out  using  commercially 
available  kits.  Circulating  anti-HCV 
antibodies  were  detected  using  Murex 
enzyme  immunoassay  kit  (Murex  anti-
HCV,  Version  V;  Murex  Diagnostics; 
Dartford, England). The presence of HCV-
RNA in patients' sera was detected by real-
time  polymerase  chain  reaction  (PCR) 
using the Amplicor test (Roche Diagnostic 
Systems; Meylan, France). Olfat Hammam et al  
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Immunohistochemical analysis 
    Immunohistochemical  reaction  was 
performed using an avidin biotin complex 
(ABC)  immunoperoxidase  technique 
according  to  Hsu  and  Raine,  1981  using 
anti  human  Fas  and  FasL  on  paraffin 
sections; dewaxed  in  xylene  and  hydrated 
in  descending  grades  of  ethanol. 
Endogenous  peroxidase  activity  was 
quenched  by  incubation  in  3%  hydrogen 
peroxide  in  100%  methanol  for  20  min. 
Antigen  retrieval  was  performed  by 
microwaving the sections in citrate buffer 
(PH  6.0)  for  15  min  at  700  W.  Sections 
were incubated overnight  at 4°C with  the 
anti-human primary antibodies against Fas 
and  Fas  Ligand  (purchased  from  Santa 
Cruz  Biotechnology  Inc.;  Santa  Cruz, 
USA)  monoclonal  antibody,  diluted  at 
1:100,  1:150  respectively  in  BPS.  Next 
day,  after  thorough  washing  in  PBS,  the 
sections were incubated with streptavidin-
biotin-peroxidase  preformed  complex  and 
using  a  peroxidase/DAB  (3,  3'-
diaminobenzidine)  enzymatic  reaction. 
Staining  is  completed  by  5-10  minutes 
results in a  
brown-colored  precipitate  at  the  antigen 
site.  The  cell  nuclei  were  counterstained 
with Mayer's hematoxylin. The cover slips 
were mounted using Dpx.  
      Positive and negative control slides for 
each  marker  were  included  within  each 
session. As a negative control, liver tissue 
section  was  processed  in  the  above 
mentioned  sequences  but  the  omission  of 
the  primary  antibody  and  PBS  was 
replaced. 
The  scoring  of  Fas  and  FasL  in 
liver  tissue  was  based  on  intensity  and 
extensiveness  (by  percentage  population) 
of  the  positively  stained  cells.  Both 
parameters were scored on a scale of 0-3 
as follows:  
(1)Intensity:                                              
0 = negative staining (-)                             
1 = weakly positive staining (+)                 
2 = moderately positive staining (++)         
3 = strongly positive staining (+++)    
(Chen et al, 2003) 
(2) Range:                                                  
0 = negative                                                
1 = positive staining in < 10% of cells       
2 = staining in 10%-50%                            
3 = staining in > 50% of cells               
(Itoi et al, 2004) 
            
Liver sections  were  examined by 
Zeiss  light  microscopy  at  power  X400, 
X200  and  X100  for  both  markers;  the 
number of positively stained cells with the 
highest expression was semi-quantitatively 
recorded within ten successive fields were 
counted  /  section  and  the  final  value 
represents the mean. Zero percentage was 
given  to  unstained  sections. Early Detection of Hepatocellular Carcinoma on top of Liver Cirrhosis….  
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Measurements of Serum Soluble Fas 
(sFas) Levels 
 Serum  Fas  levels  were  assayed  using  a 
sandwich  enzyme-linked  immune-sorbent 
assay  kit  (Biosource  International, 
Camarillo,  California,  USA)  according  to 
the  manufacturer's  instructions.  Briefly, 
diluted  serum  samples  and  standard  were 
added  in  duplicate  to  96-well  microtitre 
plates  coated  with  Fas  antibody  and 
another  biotinylated  Fas  antibody  was 
added.  The  plate  was  incubated  at  room 
temperature  for  1  h,  followed  by 
incubation  with  a  streptavidin  - 
horseradish  peroxidase  conjugate  for  30 
min.  A  solution  including  the  stabilized 
chromogen  was  added  to  each  well  and 
incubated for 30 min at room temperature. 
The reaction  was stopped  by adding  1  N 
sulfuric  acid.  The  optical  density  was 
measured at 450 nm wavelength using an 
ELISA  reader  (Bio  Rad).  The 
concentration  of  sFas  in  serum  samples 
was  determined  from  the  standard  curve. 
All  assays  were  conducted  in  duplicates, 
and  the  mean  concentration  of  sFas  was 
calculated. 
Electron Microscopic and Immunoelectron 
Microscopic  Examination  of  Peripheral 
Blood  Monocytic  Cells  (PBMNCs)  using 
Agarose  Cell  Block  Technique  (Mansy, 
2004).  
Solidified  agarose  blocks  of 
separated cells were refixed in buffered  
4%  glutaraldehyde  for  1  hour  then 
postfixed  in  2%  osmic  acid  for  1  hour, 
dehydrated  in  ascending  alcohol,  then 
infiltrated  and  embedded  in  epoxy  resin. 
Ultrathin  sections  were  performed  using 
Leica  Ultramicrotome  (Leica 
Microsystems  GmbH,  Ernst-Leitz-Strasse, 
Austria).  The  sections  were  stained  with 
uranyl  acetate  and  lead  citrate  and 
examined  using  Philips  Microscopic 
Electron  Microscope  208  S  (Eindhoven, 
The  Netherlands).  IEM  examination  was 
performed on other part of separated cells 
using rabbit polyclonal anti-Fas antibodies 
(Maixin-Bio)  as  above  method  of 
Immunohistochemical  analysis  then 
processed  into  agarose  cell  block  and 
prepared for EM examination as above. 
 
Statistical analysis 
Statistical  evaluation  of  results 
was  done  using  SPSS  computer  program 
(version  12  windows).  Results  were 
expressed  as  mean  ±  standard  deviation 
(SD) or number (%). Comparison between 
the mean values of different parameters in 
the different groups were performed using 
one  way  analysis  of  variance  (ANOVA) 
with  post  hoc  using  least  significant 
difference.  Correlation  between 
parameters  was  performed  using 
Spearman’s rank correlation coefficient (r) 
(Petei and Sabin, 2001).  P value <  0.05 
was considered significant and < 0.01 was 
considered highly significant. 
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Results: 
Hepatic Expression of Fas/ FasL antigen  
Fas/FasL  protein  was  observed  in  the 
membrane  ±  cytoplasm  of  hepatocytes 
with occasional perinuclear staining. In the 
current  study,  normal  liver  specimens 
showed  faint  Fas  protein  expression  and 
no  detectable  FasL  protein  expression. 
Both antigens were significantly increased 
in the diseased groups (p<0. 01) compared 
to  the  control  specimens  (Table  I,  II  and 
III).  In  CHC,  Fas  was  detected  among 
infiltrating  lymphocytes  at  the  advancing 
edges  of  piecemeal  necrosis  (interface 
hepatitis).  Moreover,  FasL  protein  was 
expressed  dominantly  in  the  infiltrating 
mononuclear  cells  in  the  portal  area  and 
hepatic sinusoid. Our data (Table I, II and 
III)  showed  a  progressive  Fas  and  FasL 
increase  from  CHC  without  cirrhosis  to 
CHC  with  cirrhosis.  Hepatic  Fas 
expression  was  significantly  decreased  on 
comparing  HCC  to  cirrhotic  patients 
p<0.5.  On the other hand FasL expression 
in  HCC  group  showed  a  non  significant 
difference  compared  to  CHC  with 
cirrhosis.  
       In  CHC,  apoptotic  Fas  and  FasL 
proteins  expression  was  significantly 
increased  with  the  necroinflammatory 
activity  and  the  advancement  of  fibrosis 
according  to  the  METAVIR  scoring 
systems (table IV and V) (Figures 1and 2). 
Serum level of sFas 
Concentrations  of  studied  parameter  in 
CHC,  HCC  patients  and  normal  controls 
are  shown  in  Table  I,  IV,  and  V.  The 
serum  level  of  sFas  in  both  HCC  and 
cirrhotic patients were significantly higher 
than  those  of  normal  controls  and  CHC 
without  cirrhosis  (P<0.01),  but  there  was 
no significant difference between cirrhosis 
and HCC patients.  
 
Correlation  analysis  between  different 
studied  parameters  was  demonstrated  in 
(table VI). 
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Table (I): Mean ± SD of the studied parameters in all groups 
HCC 
(n=30) 
CHC with cirrhosis 
(n=30) 
CHC without 
cirrhosis 
(n=30) 
 
Control 
(n=10) 
 
27.3±5.6
 ac   61.36 ±4.69
 ab   25.0 ±5.74
a   1.8 ± 0.8   Tissue Fas  
45.32±6.41
 ab   49.83 ±8.20
 ab   33.46 ±11.91
a   00 ± 00   Tissue FasL   
762.18±437
 ab   814.94±362
  ab   238.27± 135.29
 a   165.5 ± 45.6   sFas   
pg/ml  
ap Statistically significant from control group (p<0. 01).  
bp Statistically significant from CHC without cirrhosis group (p <0. 01).  
cp Statistically significant from cirrhosis group (p <0.01)  
 
Table (II): Tissue Expression of Fas Immunostain in Liver Tissue 
Histopathologic Diagnosis (n)  Positive Cases 
 
   No         % 
Range %  Intensity% 
<10%  10%-50%  >50%  +  ++  +++ 
Controls (10)  2          20  2  -  -  2  -  - 
CHC without cirrhosis (30)  10        33.3
a  2  8  -  3  7  - 
CHC with cirrhosis (30)  16        54.3
 ab  5  6  5  4  8  4 
HCC (30)  13        43.3
 abc  1  5  7  -  6  7 
ap<0.01 significant difference relative to control group. 
bp<0.05 significant difference relative to CHC without cirrhosis. 
cp<0.05 significant difference relative to CHC with cirrhosis. 
 
 
Table (III): Tissue Expression of FasL Immunostain in Liver Tissue 
Histopathologic Diagnosis (n)  Positive Cases 
 
   No         % 
Range %  Intensity% 
<10%  10%-50%  >50%  +  ++  +++ 
Controls (10)  0          0  -  -  -  -  -  - 
CHC without cirrhosis (30)  13       43.3
 a  3  10  -  8  5  - 
CHC with cirrhosis (30)  17       56.6
 ab  6  6  5  4  8  5 
HCC (30)  16        53.3
ac  2  7  7  -  7  9 
ap<0.01 significant difference relative to control group. 
bp<0.05 significant difference relative to CHC without cirrhosis. 
cp<0.05 significant difference relative to CHC with cirrhosis. 
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Table (IV): Mean ± SD of the studied parameters according to METAVIR activity scoring 
system in CHC with or without cirrhosis groups. 
 
  A1  (n=28)   A2  (n=18)   A3(n=14)  
Tissue Fas   23.57 ± 5.75   27.500 ± 3.54   43.00 ± 4.43
ab  
Tissue FasL   17.14 ± 4.23   20.00 ± 7.32   45.40 ± 6.42
ab  
s Fas pg/ml   210.4 ± 23.2   395.8 ± 41.4
a   447.5 ± 51.7
ab  
ap Statistically significant from A1 group (p<0. 01).  
bp Statistically significant from A2 group (p<0.01).  
 
Table (V): Mean ± SD of he studied parameters according to METAVIR fibrosis scoring 
system in CHC with or without cirrhosis groups. 
 
  F1 
(n=24) 
F2 
(n=15) 
F3 
(n=14) 
F4 
(n=7) 
Tissue Fas  17.40 ± 6.21  19.759 ± 9.76  23.04 ± 2.08 
a  33.28 ± 5.16
abc 
Tissue FasL  15.160 ± 5.02  18.75 ± 1.30  21.41 ± 2.28
ab  28.42 ± 6.06
ab 
s Fas pg/ml  200.4 ± 47.1  250.3 ± 33.6  260.4 ± 54.7
a  340.3 ± 65.4
abc 
ap Statistically significant from F1 group (p<0. 01).  
bp Statistically significant from F2 group (p<0.01).  
cp Statistically significant from F3 group (p<0.01).  
 
Table (VI): Correlation of tissue expression of different parameters in studied groups 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
P value 
Correlation 
coefficient ( r) 
Parameters 
>0.001  0.753  Tissue Fas versus  Tissue FasL 
>0.05  - 0.321  Tissue Fas versus   sFas pg/ml 
>0.01  0.682  Tissue FasL versus  sFas pg/ml Early Detection of Hepatocellular Carcinoma on top of Liver Cirrhosis….  
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Figure 1: Immunostain for Fas monoclonal antibody, A) a case of CHC without cirrhosis, 
A1F1 showing mild expression of Fas as membranous ± cytoplasmic stain in the hepatocytes 
and  in  lymphocytes  at  the  periportal  area  (IHC,  DAB,  X  200).B)  a  case  of  CHC  with 
cirrhosis, A2F2, showing moderate expression of Fas as membranous ± cytoplasmic stain  in 
the hepatocytes and in lymphocytes at the periportal area (IHC, DAB, X 200).C) a case of 
CHC with cirrhosis,  A2F3, showing cirrhotic nodule with moderate to marked expression of 
Fas  as  membranous  ±  cytoplasmic  stain  in  the  hepatocytes  and  in  lymphocytes  at  the 
periportal area ( IHC, DAB, X 100). D) a case of moderately differentiated HCC showing 
mildly expressed Fas in the cytoplasm of hepatocytes ( IHC, DAB, X400) Olfat Hammam et al  
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Figure  2:  Immunostain  for  Fas  ligand  monoclonal  antibody,  A)  a  case  of  CHC  without 
cirrhosis A1F1 showing mild expression of Fas ligand as cytoplasmic stain in the hepatocytes 
(IHC, DAB, X200), B) a case of CHC with cirrhosis A2F2 showing moderate expression of 
Fas ligand as cytoplasmic stain in the hepatocytes (IHC, DAB, X200), C) a case of CHC with 
cirrhosis  showing  cirrhotic  nodule  with  moderate  expression  of  Fas  ligand  as  cytoplasmic 
stain in  the  hepatocytes.  (IHC,  DAB,  X100), D)  a  case  of  moderately  differentiated  HCC 
showing moderate expressed Fas ligand in the cytoplasm of hepatocytes (IHC, DAB, X200). 
Discussion 
Apoptosis is central for the control 
and  elimination  of  viral  infections.  In 
chronic  HCV  infection,  enhanced 
hepatocyte apoptosis and up-regulation  of 
the  death  inducing  ligands  occur. Early Detection of Hepatocellular Carcinoma on top of Liver Cirrhosis….  
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Nevertheless,  HCV  infection 
persists in the majority of patients (Bantel 
and  Schulze,  2003).  The  impact  of 
apoptosis in chronic HCV infection is not 
well  understood.  It  may  be  harmful  by 
triggering  liver  fibrosis,  or  essential  in 
interferon  induced  HCV  elimination 
(Fisher  et  al.,  2007).  In  addition,  escape 
from the immune surveillance may play an 
important  role  in  tumor  outgrowth  and 
metastasis.  
The  Fas  receptor/ligand  system 
including  soluble  forms  is  the  most 
important  apoptotic  initiator  in  the  liver 
(Pelli et  al.,  2007).  Dysregulation  of  this 
pathway  may  contribute  to  abnormal  cell 
proliferation and cell death (Kornmann et 
al,  2000)  and  is  regarded  as  one  of  the 
mechanisms  preventing  the  immune 
system  from  rejecting  the  tumor  cells 
(Nagao  et  al,  1999).  In  this  study  the 
immunohistochemical  expression  of  Fas 
and  FasL  was  determined  using  specific 
monoclonal  antibodies.  In  normal  liver, 
Fas  was  faintly  expressed  on  cytoplasm 
and  membranes  of  hepatocytes,  while 
FasL  was  negative.  This  result  was 
consistent with those of Roskamset et al. 
(2000) and Leithauser et al.( 1993). Data 
also  showed  increase  expression  of  Fas 
receptor and ligand in hepatocytes in liver 
specimens  from  CHC  patients  with  and 
without  cirrhosis  as  compared  with 
controls.  Hepatic  Fas  expression  was 
found to be elevated in chronic hepatitis B 
(Mochizuki et al, 1996), chronic hepatitis 
C  (Hiramatsu  et  al.,  1994)  and  (El 
Bassiouny  et  al.,  2008)  and  acute  liver 
failure  (Galle  et  al,  1995).  Moreover,  a 
progressive  Fas  and  FasL  increase  from 
CHC  without  cirrhosis  to  CHC  with 
cirrhosis was also observed (Bortolami et 
al.,  2008).  Our  results  suggest  that 
"suicide"  and  "fratricide"  mechanisms 
proposed  by  Galle  et  al.(  1995)  in  the 
study of alcoholic liver cirrhosis may also 
work in liver cirrhosis after viral hepatitis 
C  and  may  explain  the  mechanism  by 
which  apoptosis  might  be  involved  in  the 
pathogenesis  of  liver  cirrhosis. 
"Fratricide",  induced  by  ligation  of  Fas 
receptor and FasL expressed on the surface 
of  adjacent  cells  while  "suicide",  induced 
by  binding  of  FasL  expressed  by 
hepatocytes  to  Fas  on  the  surface  of 
themselves.  
According  to  METAVIR  activity  score 
system,  the  up  regulation  of  hepatic  Fas 
expression  demonstrated  in  our  study  in 
CHC patients was in accordance with the 
severity  of  liver  inflammation.  Similar 
results  were  obtained  by  Hayashi  and 
Mita, 1997. The histological activity index 
(HAI)  revealed  more  expression  of  Fas 
antigen  in  liver  tissues  with  active 
inflammation than in  those without  active 
inflammation (El Bassiouny et al., 2006). 
When  HCV-specific  T-cells  migrate  into 
hepatocytes  and  recognize  the  viral 
antigen  via  the  T-cell  receptor,  they 
become  activated  and  express  FasL  that 
can transduce the apoptotic death signal to Olfat Hammam et al  
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Fas-bearing  hepatocytes  (Hayashi  and 
Mita, 1997) and (Galle et al, 1995). This 
was proved in our study by the prominent 
expression  of  FasL  protein  in  the 
infiltrating mononuclear cells in the portal 
area  and  hepatic  sinusoid  .Thus,  the  Fas 
system plays an important role in liver cell 
injury by HCV infection. Our results also 
demonstrate that the expression of Fas and 
FasL  increased  in  the  course  of  liver 
fibrosis.  Several  studies  have 
demonstrated  increased  expression  of  Fas 
and  FasL  in  the  course  of  liver  fibrosis, 
which is the  most serious consequence  of 
chronic  liver  injury  (El  Bassiouny  et  al, 
2008), (Zhang et al, 2006) and (Akazawa 
and Gores, 2007). Experimentally, the up 
regulation  of  Fas  expression  occurs  on 
stimulation  with  interferon-gamma 
released  from  T-cells  (Kawamura  et  al., 
2000).  Hepatic  fibrogenesis  accompanied 
by  hepatocellular  necrosis  and 
inflammation  was  also  suggested  to  be 
caused  by  cytokines  and  transforming 
growth  factor-beta-1  released  by  Kupfer 
cells  and  infiltrating  T-lymphocytes  (El 
Bassiouny et al, 2008). 
Because  hepatic  fibrosis  is 
associated with a high incidence of HCC, 
it was speculated that Fas expression may 
be  involved  in  the  incidence  of  HCC 
(Hirashima et al, 2002) and (Kamegaya 
et al, 2005). In HCC liver biopsies, FasL 
showed  cytoplasmic  positivity  in 
hepatocytes in areas of interface hepatitis. 
Strong expression of Fas as well as FasL 
in the hepatocytes immediately adjacent to 
HCC  was  a  constant  finding.  Within  the 
HCC  biopsies,  FasL  expression  was 
variable, but present only in a minority of 
cells.  Fas  varied  from  a  diffuse 
honeycomb  pattern  to  focal  positivity  in 
occasional cells.  
In  recent  years,  there  is 
accumulating  evidence  showing  that  sFas 
plays  an  important  role  in  modulation  of 
apoptosis  (Hiramatsu  et  al.,  1994).  sFas 
was capable of inhibiting hepatic apoptosis 
by binding to FasL or anti-Fas anti-bodies 
in competition with membrane-bound Fas. 
sFas  protein,  composed  of  the  extra 
cellular  region  of  Fas  receptor  and  Fc 
sequence  of  human  IgG,  inhibited  the 
activity  of  cytotoxic  T-lymphocytes  in  a 
dose-dependent  manner  (Peng  et  al, 
2001).  Midis  et  al.(  1996)  reported  that 
patients  with  non-haematopoietic 
malignancies  exhibit  elevated  sFas  levels 
compared to normal controls and that sFas 
can  be  synthesized  and  released  in  the 
culture supernatants of human solid tumor 
explants. They also found that the relative 
elevation  of  sFas  levels  in  non-
haematopoietic cancer patients might be in 
consistence  with  both  disease  stage  and 
tumor  burden.  Many  researchers  reported 
that  serum  sFas  levels  in  patients  with 
HCC were  significantly higher  than  those 
in  healthy  adults  (El  Bassiouny  et  al, 
2008) and (Peng et al, 2001).  Judo et al, 
1998  also  reported  that  sFas  level  was 
related with the number of tumor nodules, Early Detection of Hepatocellular Carcinoma on top of Liver Cirrhosis….  
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but not with its size of the solitary nodule. 
In  patients  with  solitary  HCC  nodule, 
serum sFas levels fell rapidly after surgical 
resection,  and  went  undetectable  in  one 
week.  This  evidence  suggested  that  sFas 
was  generated  by  tumor  cells  or  at  least 
tumor  related.  sFas  mediated  a 
prereceptorial resistance of Fas-expressing 
hepatocytes  by  antagonizing  FasL  killing 
of  infiltrating  CTLs.  Fas-bearing  tumor 
cells thus were saved by sFas from the fate 
of  apoptosis  and  escape  the  immune 
surveillance.  Our  data  revealed 
significantly  higher  serum  sFas  levels  in 
HCC patients than those in healthy adults, 
but  shown  no  significant  difference 
between  the  levels  in  HCC  and  liver 
cirrhosis  patients.  This  phenomenon  may 
be  due  to  relatively  high  expression  of 
FasL  in  HCC  cells,  and  sFas  cleaved  by 
metalloproteinases  from  the 
transmembrane  domain  might  be  capable 
of  binding  to  sFas,  thus  accuracy  of  the 
measurement  was  influenced.  A  linear 
correspondence  between  liver  tissue 
expression  and  serum  levels  of  sFas  was 
also detected. 
In  Conclusion,  apoptosis  and  the 
Fas  system  were  significantly  involved  in 
the  process  of  liver  cirrhosis  converting 
into  hepatocellular  carcinoma.  Down-
regulation of Fas expression, up regulation 
of  FasL  expression  in  hepatocytes  and 
elevation  of  serum  sFas  level  were 
important  in  tumor  evasion  from  immune 
surveillance and in hepatic carcinogenesis.  
Therefore warranted and draw  the 
attention to the use of these components of 
the Fas system as an attractive target for 
anticancer  therapy.  In  addition,  the  linear 
correspondence  between  liver  tissue 
expression  of  Fas  and  its  serum  levels 
suggest that they could be considered as a 
predictive  marker  for tumorogenesis  in 
HCC. 
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ذبكلا فيلح ثلااح ىف ذبكلا مارولأ ركبولا صيخشخلا  : تلبقخسهرود   اهحاقخشه و ساف   ىطبارخلا اهبكره و  
د . ماوه جفلأ ١ د ، . ىارهز لانه ٢ د ،  . دىوحه لاع ٢ د ،  . ىلع ريهس ٣ د ،  . ىنسح نيرك ٤ د ، . ريهأ ىولح ة ٥ د ،  . سنأ ذجهأ ٦  
١ -    خٛثزؼنا زصي خٚرًٕٓع ،حشٛغنا ،سبحثلأن رٔدٕٛر ذٓؼي ،خٛعٕنٕصبجنا ىسق                        
٢ -    خٛثزؼنا زصي خٚرًٕٓع ،حشٛغنا ،سبحثلأن رٔدٕٛر ذٓؼي ،وذنا ضازيأ ىسق                  
٣ -    خٚرًٕٓع ،حزْبقنا ،سٕحجنا ذٓؼًث خٛئأذنا ءبًٛٛكنا ىسق ٔ بٚشٛنبًث ٌبُسلأا ٔ تطنا ذٓؼي خٛثزؼنا زصي                          
٤ -   خٛثزؼنا زصي خٚرًٕٓع ،حزْبقنا خؼيبع ،تطنا خٛهك ،خيبؼنا خحازغنا ىسق                                      
٥ -    حذحٔ َٗٔززكنلإا زٓغًنا   ( وذنا ضازيأ ىسق ) خٛثزؼنا زصي خٚرًٕٓع ،حشٛغنا ،سبحثلأن رٔدٕٛر ذٓؼي ،               
٦   -   ذجكنا ضازيأ ىسق    خٛثزؼنا زصي خٚرًٕٓع ،حشٛغنا ،سبحثلأن رٔدٕٛر ذٓؼي ،ًٗعٓنا سبٓغنا ٔ  
ذجكنا ٌبغزس ذنٕر ٙس صٔزٛفث خثبصلإا ٍي ظربُنا ًٕ٘حنا ذجكنا ةبٓزنإ دبفػبعي ٍي  .  دلأبحي ٔ دبسٔزٛفنا زصبكر
فٛهر ُّػ ظزُٚ خثبصًنا ذجكنا بٚلاخ ٍي صهخزنا ٔ صٔزٛفنا خحفبكًن حزًزسًنا ٗػبًُنا سبٓغنا    دبئسٕئزك مهخ ٔ ذجكنبث
ٌبغزسن رٕطزٚ ٖذنا ذجكنا بٚلاخ  .  بٓربقزشي ٔ صبف خهجقزسي خُغزسًنا بٚلاخنا ٍي صهخزهن خًظًُنا دبئٚشغنا ٍي ( صبف - ر  )
 ٔ ( صبف - ص  )  ٗطثاززنا بٓجكزي ٔ ( صبف - ل  .)  ٖدبفزر ٔ بٓفئبظٔ ٔ صبفن حدبعي دبئٚشع تسزكر خَٛبغزسنا بٚلاخنا ٍكن ٔ
 زٛسكزنا .  
حبلا فذه ث :    
 ٗطثاززنا بٓجكزي ٔ صبف خهجقزسي دبئٚشع صبٛق ( صبف - ل   )  بٓربقزشي ٔ ذجكنا بٚلاخ ٗف ( صبف - ص  )  ٔ وذنا ٗف ( صبف - ر  )  ٗهػ
 وارٔلأ زكجًنا صٛخشزنا ٗف بٓياذخزسإ ىص ٍي ٔ ٌبغزسنا ذنٕر ٗف ىْرأدأ ذٚذحزن خنٔبحي ٗف خٛفًهنا ءبعٛجنا وذنا  خٛهخ
 طلاؼهن فذٓك بٓياذخزسإ ٔ ذجكنا ٖٔبًٛكنا .  
ثحبلا بىلسإ :  
  خٛثزؼنازصي خٚرًٕٓغث ُٗٛؼنا زصقنا ٔ حشٛغنبث سبحثلأنسربٓهث رٔدٕٛر ذٓؼي ٗف دلابح ٍي ،خُٛػ خئبي ًٍعر شحجنا  .
 فٛهر دٕعٔ ٌٔذث خنبح ٍٛصلاص ىُٓي ٙس صٔزٛفث خثبصلإا ٍي ظربُنا ًٕ٘حنا ذجكنا ةبٓزنإ خنبح ٍٛؼسر ٍي دبُٛػ دذخأ
 غي خنبح ٍٛصلاصٔ ذجكنبث ٖذجك َٗبغزس ورٔ بٓث خنبح ٍٛصلاص ٔ ذجكنبث فٛهر دٕعٔ  . خَربقًهن ىٛهس ذجك ٍي دبُٛػ حزشػ بَذخأ  .
صبف ٔ صبف صبٛق ىر -   صبف صبٛق ٔ ،خغسَلأأ خػبًُنا ءبًٛك ةٕهسأث ذجكنا ٗف ل -   صبف صبٛق ٔ وذنبث ص -    زٓغًنبثر
خٛفًهنا ءبعٛجنا وذنا  خٛهخ ٗهػ َٗٔززكنلإا .  
جئاخنلا :  
  حدبٚس دذعٔ   صبفن ٗئبصحلإا داذزػلإا ٖٕزسي ٗنإ ذهصٔ خظٕحهي -    ذجكنا وارٔأ ٔ ٖذجكنا فٛهزنا دلابح ٗف وذنبث ص
 وارٔأ دلابحٔ ٖذجكنا فٛهزنا دلابح ٍٛث فلازخإ ذعٕٚ ىن ٍكن ٔ ،فٛهر ٌٔذث ذجكنا ةبٓزنإ ٔ ىٛهسنا ذجكنبث ًبَربقي خَٛبغزسنا
خَٛبغزسنا ذجكنا  . صبف ٔ صبف صبٛق -    ذجكنا بٚلاخث ل  طٚزًنا ذجكهن خًُعزًنا دبػًٕغي سلاضنا ٗف لذزؼي عبفررإ زٓظأ
ىٛهسنا ذجكنا خػًٕغًث ًبَربقي  .  فٛهزنا حدبٚس غي ًبٛغٚرذر ًبػبفررإ ددادسإ ىص فٛهر ٌٔذث ذجكنا ةبٓزنإ غي دلالاذنا ِذْ ذؼفررإ
ذجكنا وارٔأ رٕٓظ غي ذعفخَإ ىص  . صبف ٍٛث خٛجهس خندبجزي خقلاػ دذعٔ -   صبف ٔ وذنبث ص -   حذزؼي زٛغ بُٓكن ٔ ذجكنبث ل .  كنذك
صبف غفررإ -   ذجكنا بٚلاخ دٕي حدبٚس غي وذنبث ر  .  
جاخننخسلإا :  
  فٛهزًنا ذجكنا ٗف ذجكنا ٌبغزس ذنٕزث خًٛٛظُر خقلاػ بٓن صبف خهجقزسي خيٕظُي  .  عبفررإ ٔ ،صبف خهجقزسي ربٓظإ ٗف ضبفخَإ
صبف عبفررإ ٗنإ خفبظلإبث ،ذجكنا بٚلاخ ٗف ٗطثاززنا صبف تكزي ربٓظإ ٗف -    ص كنا ٌبغزس ذنٕر ٗنإ ٖدؤر وذنبثEarly Detection of Hepatocellular Carcinoma on top of Liver Cirrhosis….  
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